Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2 Lyme Vaccine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Subject is 18 to 70 years old at the time of screening~* Subject has an understanding of the study, agrees to its provisions, and gives written informed consent prior to study entry~* Subject is generally healthy, as determined by the investigator's clinical judgment through collection of medical history and the performance of a physical examination~* If female of childbearing potential, presents with a negative urine pregnancy test, and agrees to employ adequate birth control measures for the duration of the study~Additional inclusion criterion for seropositive subjects in Section 2 only:~- Subject is seropositive for Borrelia burgdorferi sensu lato (s.l.) antibodies at study entry~Main Exclusion Criteria:~* Subject has a physician-diagnosed chronic illness related to Lyme borreliosis (LB) or active LB~* Subject has been treated for LB with antibiotics within 3 months of study entry~* Subject had a tick bite within 3 weeks prior to screening or first vaccination~* Subject has a history or active infection with Babesia microti (babesiosis) or Anaplasma phagocytophilum (ehrlichiosis)~* Subject currently has or has a history of significant cardiovascular, respiratory (including asthma), metabolic, neurological, hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder~* Subject has clinically significant abnormal laboratory values at screening~* Subject currently has or has a history of immunodeficiency~* Subject tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)~* Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that could be expected to influence immune response.~* Subject has a history of anaphylaxis or severe allergic reactions~* Subject has received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study~* Subject is pregnant or lactating at the time of study enrollment~Additional exclusion criterion for subjects in Section 1 and seronegative subjects in Section 2:~- Subject is seropositive for Borrelia burgdorferi sensu lato (s.l.) antibodies at study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Primary vaccination in seronegative subjects (Type: EXPERIMENTAL): None
- Booster vaccination in seronegative subjects (Type: EXPERIMENTAL): None
- Primary + booster vacc. (seronegative + seropositive subjects) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).